spacer
home > pmps > autumn 2019 > reliable temperature control
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Reliable Temperature Control





Most biologics require controlled temperature conditions throughout their lifecycle to maintain their efficacy and integrity. By some industry estimates, 25% of such drugs degrade or go to waste due to temperature excursions that result in $16 billion in economic losses and patient safety issues. The industry should aggressively adopt advances in packaging and information technologies such as Internet of Things (IoT) and blockchain to prevent temperature excursions in cold chains.

The Next Big Growth Markets

According to research, the biologics and biosimilar market is expected to reach $399.5 billion by 2025. More than 50% of new drug approvals in 2017 are biologics that require temperaturecontrolled environments, a trend that is anticipated to continue.

Biologics are large molecule drugs that contain a living organism or a component thereof, such as recombinant DNA and deactivated viruses. Biologic drugs are sensitive to their environmental conditions such as temperature, light exposure, humidity, shock, and vibrations and can degrade or spoil when exposed to conditions outside their stability range for a long period of time. Of all the environmental conditions, temperature stands out as the single biggest cause of drug degradation and spoilage.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Sujan Thanjavuru is a digital transformation thought leader in the life sciences industry. For over 20 years, Sujan has been partnering with life sciences companies to help reduce time to market of new products and drive enterprise transformation across their value chain. He is also the founder of two health IT start ups, Clinical Data and SafeRxp. Both startups have developed innovative cloudbased cognitive platforms in partnership with Carnegie Mellon University, US. Sujan continues to build innovative new IT platforms that attempt to solve structural industry problems such as counterfeit drugs, broken cold chains, high cost of drug development, and serious adverse drug reactions.


Print this page
Send to a friend
Privacy statement
News and Press Releases

A new anti-tumour treatment is one step closer to the clinic thanks to a new collaboration between In3Bio and 3P Biopharmaceuticals

[Pamplona, November 26 2019] 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has been chosen by In3Bio, a UK based Biotech company, to collaborate in the development of a novel anti-tumour treatment.
More info >>

White Papers

PROTEIN:PROTEIN INTERACTION ANALYSIS

IBA GmbH

Groth et al., 2007 and Jasencakova et al., 2010 Protein:protein-interactions (PPI) govern almost all important processes in living organisms. Thus, their rapid and accurate determination and investigation is a major challenge in life sciences. The extremely efficient and fast One-STrEP (Twin-Strep) system is suitable for the isolation of functional protein complexes and subsequent mass spectrometry analysis leads to the identification of protein complex components (Junttila et al., 2005) as it is shown in the following studies.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement